A Next Generation Stem Cell Therapeutics Company Investor Presentation: Cynata Therapeutics Limited June 2020
Important Information This presentation has been prepared by Cynata Therapeutics Limited. (“Cynata” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The distribution of this presentation may be restricted by law and you should observe any such restrictions. Forward looking statements This presentation contains certain forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation). www.cynata.com 2
Cynata Therapeutics is a clinical stage biotech with a highly scalable, proprietary platform for developing stem cell therapeutics Our focus Financial information Share price (9-June-20) A$0.665 Utilise our proprietary Cymerus TM platform technology to develop commercially scalable Shares on issue 117m cellular therapeutic products to treat serious A$77.8m chronic disorders Market capitalisation 1 ~(US$53m) About Cynata Therapeutics Cash 2 A$15.2m Debt - ▪ Cynata is an Australian stem cell and regenerative medicine company that is developing a therapeutic Enterprise value A$62.6m stem cell platform technology, Cymerus, using discoveries made at the University of Wisconsin- Madison Top shareholders ▪ Cynata has licensed its first product, CYP-001 for graft-versus-host-disease (GvHD) to Fujifilm, with the 9.9% intention to license Cymerus technology across a range of serious disorders 7.4% ▪ Cynata’s proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for Board and management 5.8% therapeutic use, which is the ability to achieve economic manufacture at commercial scale www.cynata.com 1. USD/AUD = 1.46; 2. Cash incorporates A$6.9m as at 31 Mar 2020, adjusted for the A$3.55m Placement announced 22 Apr 2020 and A$4.8m SPP announced 27 May 2020 3
Recent Developments: Optimising clinical programs Progressing clinical Ethics approval for FUJIFILM partnership ✓ ✓ ✓ development COVID-19 clinical trial driving GvHD Phase 2 ▪ Accelerated planning and rapidly ▪ FUJIFILM endorsement via license ▪ Osteoarthritis 440 patient Phase 3 achieved ethics approval validates Cymerus platform; Fuji clinical trial approved; funded by the funding development and NHMRC ▪ MEND 1 clinical trial will build on commercialisation ▪ CLI Phase 2 clinical trial approved by Cynata’s strong pre-clinical results in ▪ Phase 2 GvHD clinical trial expected MHRA ARDS, sepsis and CRS, all of which end 2020 are common hallmarks of severe ▪ COVID-19 Phase 2 approved COVID-19 cases Building on strong Fully funded GvHD Multiple Phase 2/3 ready pre-clinical results product development indications Active commercial discussions ongoing www.cynata.com 1. MEND = MEseNchymal coviD-19 trial 4
MSCs have potential utility in complications arising from a COVID-19 infection ▪ Increased global interest in the potential of MSCs to treat complications of COVID-19, representing external validation and early studies demonstrating potential utility 1 ▪ COVID-19 is a respiratory virus that in some patients causes severe complications, particularly involving the lungs ▪ ARDS and sepsis, together with cytokine release syndrome (CRS), are the leading causes of death in COVID-19 patients o ARDS is an inflammatory process leading to build-up of fluid in the lungs and respiratory failure; ARDS makes up ~10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation 2 ; death occurs in more than one-third of patients o Sepsis , commonly referred to as blood poisoning, is an over-reaction of the immune system to infection, leading to ~6m deaths every year 3 o CRS is a systematic inflammatory immune response, with reactions ranging from mild to life threatening ▪ Cynata has generated compelling data from pre-clinical studies investigating the potential of its MSCs in these indications, as they each represent significant unmet needs with broader applications to Cynata’s clinical development beyond COVID-19 Cynata plans to leverage recent increased interest to accelerate its development program and validate its technology for multiple indications and in multiple regions Note: MSCs are not inherently antiviral and are not a vaccine. www.cynata.com 1. Leng, G. et al., Aging & Disease, 11: 216 April 2020; 2. Bellani G,, et al.. Jama. 2016;315(8):788.E 3 . Not COVID-19 induced deaths (Source: World Health Organization)
Cynata’s COVID-19 clinical development program is underpinned by strong pre- clinical and clinical results Cynata’s data supports utility of Cymerus MSCs, confirming that Compelling pre-clinical results in diseases they: which can arise from a COVID-19 infection: Significantly reduce levels of pro-inflammatory cytokines Study demonstrated effectiveness of Increase both anti-inflammatory proteins and ✓ regulatory T cells Cymerus MSCs in acute respiratory distress syndrome (ARDS) Have a strong safety profile ARDS Results show that Cymerus MSCs are ✓ highly effective in a model of pneumonia induced sepsis Sepsis ✓ Model demonstrated Cymerus MSCs significantly ameliorate the effects of cytokine release syndrome (CRS) CRS Cynata is now engaging with multiple parties, and considering collaboration and partnering opportunities as they arise www.cynata.com
Recommend
More recommend
